GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice

A single-molecule agonist targeting GLP-1R, GIPR, and PPARα/γ/δ receptors (GLP-1–GIP–lanifibranor) demonstrates therapeutic efficacy in correcting obesity and diabetes in mouse models through synergistic metabolic pathways. Published in Nature, the study highlights its potential for treating obesity-linked metabolic dysfunction.